|Bid||112.75 x 400|
|Ask||120.48 x 200|
|Day's Range||118.20 - 120.47|
|52 Week Range||92.65 - 143.37|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||154.00|
NEW YORK, March 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Zacks Market Edge Highlights: Scotts Miracle-Gro, GW Pharmaceuticals, Innovative Industrial Properties and AbbVie
LONDON and CARLSBAD, Calif., March 13, 2018-- GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid ...
LONDON and CARLSBAD, Calif., March 05, 2018-- GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid ...
A Schedule II classification would have a number of unintended consequences that legalization enthusiasts are probably overlooking.
Despite a strong performance Friday, U.S. cannabis stocks had a bad week, with the United States Marijuana Index , which tracks 15 of the largest marijuana stocks in the U.S., losing roughly 4 percent ...
NEW YORK, NY / ACCESSWIRE / March 1, 2018 / It's been an exciting week for the marijuana sector in the market. Cronos shares skyrocket after the stock made its debut on the NASDAQ this week. GW Pharmaceuticals ...
This cannabinoid-based drug developer could be more pivotal than you realize in helping to shape U.S. cannabis policy in the years to come.
LONDON and CARLSBAD, Calif., Feb. 27, 2018-- GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid ...
The US marijuana industry has a lot of potential to grow and presents a good investment opportunity, although there is some uncertainty regarding the regulations. On the one hand, medical marijuana has been legal in 28 states and the District of Columbia and eight states allow the sale and possession of cannabis for both medical and recreational use. […]
The United States Marijuana Index, which tracks 15 of the largest marijuana stocks in the U.S., lost 7.5 percent in the four days the market was open after President's Day. The North American Marijuana ...
AbbVie (NYSE:ABBV) took center stage in yesterday’s biotechnology news arena with its potentially groundbreaking Alzheimer’s partnership but the company isn’t stopping there. As we head into the end of the week, news has hit press that a partnership between AbbVie and Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has just produced some trial data and both companies are […] The post Here Are Today’s Biotech Movers: Abbvie, Neurocrine and GW Pharmaceuticals appeared first on Market Exclusive.
GW Pharmaceuticals' CBDV drug strikes out in a phase 2a study. But there's a much more important catalyst ahead.
There is no doubt that the marijuana industry in the US has a lot of growth potential. The sale of medical and recreational weed is expected to reach $30 billion by 2021 from $6.50 billion this year. However, the opportunities to invest in the industry are pretty limited. There are many cannabis companies trading on […]
Shares of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) tumbled nearly 5% in after-hours trading Wednesday, after the drug maker announced negative results with GWP42006 in adult patients with focal seizures. The Phase 2a placebo-controlled study evaluated the efficacy and safety of GWP42006, which features cannabidivarin (CBDV) as the primary cannabinoid molecule, as add-on therapy in 162 adult patients with inadequately controlled focal seizures. In the trial’s preliminary top-line results, both active and placebo arms showed similar reductions in focal seizures of approximately 40 percent.
-Study did not meet its primary endpoint-. -Company remains committed to continued development of GWP42006 for autism spectrum disorders and will continue to explore the product’ s potential within the ...
" Wonder Women Of Weed " is a bi-monthly show and column featuring accomplished female leaders in the cannabis industry, brought from a collaborative effort that includes Benzinga, Industry Power ...